All In Biotech

Drug Trial Radar · NCT04311671

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

A Randomized, Double Blind, Parallel Group Clinical Trial to Evaluate the Safety of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Treatment With Albendazole

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 12,979 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,979

Actual

Start

May 3, 2021

Primary completion

Sep 27, 2024

Study completion Sep 27, 2024

Sponsor

Lead sponsor
Medicines Development for Global HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole.

Conditions

  • Onchocerciasis

Interventions

  • MoxidectinDrug

    2 mg tablets, encapsulated for blinding

  • IvermectinDrug

    3 mg tablets, encapsulated for blinding

  • AlbendazoleDrug

    400 mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Treatment Emergent Adverse EventsTime frame: Up to 3 months

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire

    Abidjan, Côte d’Ivoire

  • Centre de Recherche pour les Maladies Tropicales Negligees

    Rethy, Ituri, Democratic Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.